Hikma Sells Ben Venue Manufacturing Facilities to Xellia

Hikma Pharmaceuticals has agreed to sell the former Ben Venue manufacturing facilities based in Bedford, Ohio, to Xellia Pharmaceuticals. Hikma acquired the Ben Venue assets from Boehringer Ingelheim in September 2014.

Under the terms of the agreement, Xellia will acquire substantial parts of the Ben Venue site, including four sterile injectable manufacturing plants, which are not currently operational. 

Hikma will retain the Quality and Development Centre, an independent building with R&D laboratories, which played a key role in the tech transfer of the Bedford products to Hikma’s own manufacturing facilities. Since the acquisition of Ben Venue, Hikma has transferred a large number of modern, high-quality machines, such as lyophlizers and filling lines, to its manufacturing facilities in Portugal, Germany, and the US.

“We are very pleased to see that Xellia plans to restart commercial operations at the Ben Venue site, which will create jobs and further support the Bedford community,” commented Said Darwazah, chairman and CEO of Hikma, in a press statement. “We have successfully transferred equipment from Ben Venue to our different manufacturing sites, and will continue to benefit from the exceptional capabilities and skills of the Quality and Development Centre and the Bedford R&D teams on-site.”

Source: Hikma